10-Q: American Well Corporation Reports First Quarter 2024 Results Amidst Platform Transition

American Well Corporation's first quarter 2024 results show a decrease in revenue and a net loss, impacted by customer churn during platform migration and increased investment in government sector products.

Summary

• American Well Corporation reported a net loss of $73.4 million for the first quarter of 2024, compared to a net loss of $398.5 million in the same period last year.
• Revenue decreased to $59.5 million from $64.0 million year-over-year, primarily due to a decline in subscription and visit revenue.
• The company experienced a decrease in subscription revenue by $3.8 million due to customer churn during the re-platforming process.
• Visit revenue also declined by $1.3 million due to lower visit volume and reduced utilization in specialty care.
• Operating expenses decreased significantly due to a large goodwill impairment in the prior year, but research and development, sales and marketing, and depreciation and amortization expenses increased.
• The company's adjusted EBITDA was a loss of $45.7 million, compared to a loss of $44.6 million in the first quarter of 2023.
• The company completed 1.7 million visits on its platform in the first quarter of 2024, consistent with the same period last year.
• 68% of visits were conducted on the Converge platform, up from 52% in the previous quarter.
• The company is investing in its government sector product, which is expected to drive revenue growth in the coming years.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is improvement in net loss compared to the previous year, the decrease in revenue and ongoing losses are concerning. The company is making strategic investments, but the overall sentiment is cautious due to the financial challenges and the risk of delisting.

Positives

• The net loss significantly improved year-over-year, decreasing from $398.5 million to $73.4 million.
• The company is making progress in migrating clients to the Converge platform, with 68% of visits now on the new platform.
• The company is investing in its government sector product, which is expected to drive future revenue growth.
• The company's cash position remains strong with $308.6 million in cash and cash equivalents.
• The company has a thumbs-up rating by patients and providers of over 90%.

Negatives

• Revenue decreased by 7% year-over-year, primarily due to customer churn during the re-platforming process.
• Subscription revenue declined by $3.8 million due to customer churn.
• Visit revenue decreased by $1.3 million due to lower visit volume and reduced utilization in specialty care.
• The company continues to operate at a loss, with a net loss of $73.4 million for the quarter.
• The company's adjusted EBITDA was a loss of $45.7 million.

Risks

• The company is experiencing customer churn due to the ongoing platform migration, which is impacting revenue.
• The company is still operating at a loss and may not achieve profitability in the near term.
• The company's stock is at risk of being delisted from the NYSE due to low share price.
• The company faces competition from existing and potential new participants in the healthcare industry.
• The company's ability to operate profitably depends on maintaining necessary licenses and complying with applicable laws and rules.
• The company is subject to risks related to cybersecurity breaches and compliance with privacy regulations.
• The company's future capital requirements will depend on many factors, and it may need to seek additional financing.

Future Outlook

The company expects to continue investing in its government sector product and to focus on migrating remaining clients to the Converge platform. They anticipate a return to normal levels of research and development spending in the coming quarters, after the majority of 2024 investment in the government sector. The company believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• Management is focused on the transformational steps necessary to reaccelerate growth during this period of transition.
• Management is focused on the migration of remaining health plan and health system clients onto the Converge platform.
• Management believes the investment in the government sector will drive revenue growth in the coming years.

Industry Context

The company operates in the digital healthcare market, which is experiencing rapid growth and increased competition. The company's focus on platform migration and government sector opportunities reflects a strategic response to these market dynamics. The shift towards hybrid care models is also a key trend that the company is addressing with its Converge platform.

Comparison to Industry Standards

• Teladoc, a major competitor in the telehealth space, reported a revenue of $646.8 million in Q1 2024, demonstrating a larger scale of operations compared to Amwell's $59.5 million.
• Similar to Amwell, other telehealth companies are also investing in platform development and expansion of services, indicating a broader industry trend towards integrated digital care solutions.
• While Amwell is focusing on migrating clients to its Converge platform, other companies are also working on improving their technology and user experience, suggesting a competitive landscape focused on innovation.
• The decrease in Amwell's revenue and the ongoing losses highlight the challenges in achieving profitability in the competitive telehealth market, a challenge faced by many companies in the sector.

Related Party Transactions

• The company has related party transactions with Cleveland Clinic, including revenue recognition of $470 and $599 for the three months ended March 31, 2024 and 2023, respectively.
• The company has related party transactions with CCAW, JV LLC, including revenue recognition of $402 and $389 for the three months ended March 31, 2024 and 2023, respectively, and a capital contribution of $1.7 million in the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders are impacted by the decrease in revenue and ongoing losses, as well as the risk of stock delisting.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may experience changes during the platform migration process.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to focus on migrating clients to the Converge platform.
• The company will continue to invest in its government sector product.
• The company will seek stockholder approval for a reverse stock split to address NYSE listing requirements.

Key Dates

Keywords

telehealth, digital health, virtual care, platform, subscription, healthcare, Converge, Amwell, software, visits